Tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
Nearly three in four patients treated with adjuvant Tagrisso were alive and disease-free at four years. Exploratory results showed Tagrisso also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease.Updated results from the pivotal ADAURA Phase III trial showed that AstraZeneca’s Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful improvement in disease-free survival (DFS) compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm)